HID-HSCT Versus IST as First-line Treatment for SAA

Exclusion Criteria

• •1. Inherited bone marrow failure syndromes (IBMFS), including Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome (SDS), etc.;
• •2. Clonal cytogenetic abnormalities or bone marrow examination suggesting pre-MDS or MDS;
• •3. Known severe allergy to ATG;
• •4. Previous allogeneic or autologous hematopoietic stem cell transplantation;
• •5. Previous solid organ transplantation;
• •6. Uncontrolled infection at enrollment, or requiring mechanical ventilation or hemodynamic instability;
• •7. Active HIV replication at enrollment, detectable HCV antibody positivity and HCV-RNA positivity within 90 days prior to enrollment, or HBsAg positivity; known seropositivity for HIV or active hepatitis C virus;
• •8. History of malignant tumors (except resected basal cell carcinoma or treated cervical carcinoma in situ);
• •9. Psychiatric disorders or other conditions that prevent compliance with study treatment and monitoring requirements;
• •10. Inability or unwillingness to sign the consent form;
• •11. Other special circumstances deemed ineligible by the investigator.